JPRN-jRCTs031220288招募中2 期
JCOG2010: Single-arm confirmatory trial of the total neoadjuvant therapy and watch and wait strategy for the patients with low rectal cancer Total Neoadjuvant Therapy and Watch and Wait strategy for Low Rectal Cancer - TOWARd
KANEMITSU Yukihide0 个研究点目标入组 105 人开始时间: 2022年8月24日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 75age old（—）
- 性别
- All
入选标准
- •(1) Endoscopic biopsy from a primary rectal lesion has been histologically diagnosed as tubular adenocarcinoma (well or moderately differentiated). Or endoscopic biopsy from a primary lesion in the anal canal has been histologically diagnosed as adenocarcinoma (rectal type) and further diagnosed as well differentiated or moderately differentiated.
- •(2) The tumor is predominantly located in the upper rectum (Ra), lower rectum (Rb), or anal canal (P).
- •(3) The lower margin of the tumor is located between the perineal reflection and the anal verge (Rb-P).
- •(4) Comprehensive diagnosis of cT2-cT3 by abdominal and pelvic contrast CT* and pelvic contrast MRI* with a slice thickness of 5 mm or less. (JSCCR guideline, 9th Edition)
- •*Contrast-enhanced CT or contrast-enhanced MRI are preferred, but plain CT or plain MRI is acceptable, respectively.
- •(5) No lymph node satisfying either 1. or 2. below is present on comprehensive diagnosis by contrast-enhanced CT* of the chest, abdomen, and pelvic region with a slice thickness of 5 mm or less and contrast-enhanced MRI* of the pelvic region.
- •1. 10 mm or more in short diameter
- •2. 7 mm or more in short diameter and one or more of the following (a)-(c)
- •(a) irregular margins
- •(b) MRI shows internal inhomogeneous low-signal areas
- •(c) Circular (long to short diameter ratio < 1.5)
- •(6) No distant metastasis.
- •(7) The maximum diameter of the tumor is less than 5 cm on comprehensive diagnosis by contrast-enhanced CT* of the abdomen and pelvis with a slice thickness of 5 mm or less, contrast-enhanced MRI *of the pelvis, and endoscopy of the lower gastrointestinal tract.
- •(8) Comprehensive diagnosis using colonoscopy and imaging studies (barium enema or abdominal/pelvic contrast CT* or CT colonography) does not reveal multiple carcinomas. However, cTis and cT1a (cancer is expected to remain in the submucosal layer and invade less than 1,000 micrometre) lesions that are expected to be curatively resectable by endoscopic resection are not considered multiple carcinomas.
- •(9) Patients must be between 18 and 75 years of age on the date of enrollment.
- •(10)Performance status (PS) is 0 or 1 according to ECOG criteria
- •(11) The patient does not wish to undergo surgical resection, the standard of care, as initial treatment, but wishes to undergo salvage treatment, including surgical resection, in the event of residual or recurrent disease.
- •(12) The patient is able to take oral intake.
- •(13)The patient has not undergone rectal resection (except for endoscopic resection), radiation therapy to the pelvic region, or any previous treatment, including treatment for other types of cancer.
- •(14)The most recent laboratory values within 14 days prior to enrollment (the same day of the week two weeks prior to the date of enrollment is acceptable) meet all of the following
- •1. neutrophil count >= 1,500/mm3
- •2. Hemoglobin >= 9.0 g/dL (no blood transfusion within 14 days prior to the date of blood collection for the test used for registration)
- •3. Platelet count >=100,000/mm3
- •4. Total bilirubin <= 2.0 mg/dL
- •5. AST<=100 U/L
- •6. ALT<=100 U/L
- •7. Serum creatinine <= 1.5 mg/dL
- •(15) Written consent to participate in the study has been obtained from the patient.
排除标准
- •(1) Active multiple cancers (simultaneous multiple cancers and multiple cancers with a disease-free interval of 5 years or less. However, multiple cancers do not include stage I prostate cancer, stage 0 or stage I laryngeal cancer that has had a complete response to radiotherapy, or cancer that has been completely resected with a 5-year relative survival rate equivalent to 95% or greater).
- •(2) Infectious diseases requiring systemic treatment.
- •(3) Have a fever of 38.0 degrees Celsius or higher at the time of registration.
- •(4) Pregnant, possibly pregnant, within 28 days postpartum, or lactating. Males whose partners wish to become pregnant.
- •(5) Patients with psychiatric disorders or psychiatric symptoms that interfere with daily life and make it difficult for them to participate in the study.
- •(6) Receiving continuous systemic administration (oral or intravenous) of steroids or other immunosuppressive drugs.
- •(7) Complicated with poorly controlled diabetes mellitus.
- •(8) Patient has uncontrolled hypertension.
- •(9) Complicated with unstable angina (angina with onset or worsening within the last 3 weeks) or a history of myocardial infarction within the last 6 months.
- •(10) Poorly controlled valvular heart disease, dilated cardiomyopathy, or hypertrophic cardiomyopathy.
- •(11) HBs antigen positive.
- •(12) HIV antibody positive.
- •(13)Has one or more of the following complications diagnosed by chest CT: interstitial pneumonia, pulmonary fibrosis, or severe emphysema.
研究者
相似试验
进行中（未招募）
3 期
JCOG1612: Single-arm confirmatory trial of the adjuvant chemoradiation for the patients with the high-risk rectal submucosal invasive cancer after the local resectioJPRN-jRCT1031180076SAITO Yutaka210
进行中（未招募）
3 期
JCOG1402: Non-randimized confirmatory trial of postoperative concurrent chemoradiotherapy (CCRT) using IMRT for patients with high-risk uterine cervical cancerPostoperative uterine cervical cancer patients with high-risk prognostic factorsJPRN-jRCTs031180194Toita Takafumi220
招募中
3 期
JCOG2011: A randomized controlled phase III trial for confirming superiority of local radiotherapy added to anti-androgen therapy for prostate cancer patients with high volume metastasis sensitive to hormone therapyhigh volume metastatic prostate cancerJPRN-jRCT1031220676KAMOTO Toshiyuki440
尚未招募
1 期
To study effect of jyotishmatyadi vati in delayed mensesCTRI/2019/10/021824Dr Tejaswinee Narendra chavan
进行中（未招募）
3 期
JCOG1017: A randomized controlled trial comparing primary tumor resection plus systemic therapy with systemic therapy alone in metastatic breast cancerMetastatic breast cancerJPRN-jRCTs031180151IWATA Hiroji600